En Es
Categories

Industry News

Global POC Infectious Disease Market to Reach USD 1.9 Billion by 2025

By Labmedica International staff writers
09 Jan 2018

Image: The global point-of-care infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025 (Photo courtesy of iStock).The global point-of-care (POC) infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025, as the emerging trend of patient-centric services and increase in complicated infectious disorders drives an upsurge in the demand for portable and accurate detection devices.

These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Portable devices with the potential to enable rapid detection of infectious diseases are revolutionizing patient care and driving the growing demand for decentralized testing settings. Additionally, increased R&D investments for the development of new products are expected to further drive the POC infectious disease diagnostics/testing market. For instance, an EU project research team has developed a new lab-on-a-disc' technology that aids in the diagnosis of various infectious diseases, including malaria. Through POC treatment, the technology enables faster diagnosis and allows precise administration of drugs, thereby driving its adoption.

HIV POC is estimated to account for the largest share of the POC infectious disease diagnostics/testing market due to the rising incidence rate of the disease. Companies are also adopting a quality management approach towards the introduction of novel tests for HIV diagnosis. TB and drug resistant TB are anticipated to witness lucrative demand over the coming years on account of their rising incidence rate, fueled further by the implementation of fully or partially integrated nano/microscale technologies for developing drug resistant TB diagnostic devices.

The demand for the development of inexpensive, rapid, simple, and accurate tests capable of simultaneously detecting multiple biomarkers is expected to contribute to the market growth. Moreover, advances in bio sensing technology for early detection with sensitivity are expected to drive revenue for the market players over the coming years.

Geographically, North America dominates the global market for POC infectious disease diagnostics/testing, due to adequate administration support, well-established healthcare framework, and extensive R&D upgradation in the region. However, the Asia Pacific market is expected to record the fastest growth over the forecast period due to the rising incidence and prevalence rates of infectious diseases in the region as well as favorable government support.

Related Links:
Research and Markets



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

24 Apr 2018
Fujifilm Showcases Extended Product Line at ECR 2018
Fujifilm Medical Systems Europe, a provider of diagnostic imaging products and medical informatics solutions, showcased its broad, enhanced line up of products and solutions at the European Congress of Radiology (ECR) 2018. The products and solutions showcased by Fujifilm at ECR 2018 focused on women’s health, healthcare IT, artificial intelligence (AI), digital radiography (DR), computed tomography (CT), computed radiography and ultrasound.
Read More
24 Apr 2018
AI Device for Diabetic Retinopathy Receives FDA Approval
The first-ever medical device to use artificial intelligence (AI) for detecting diabetic retinopathy has received marketing approval from the US Food and Drug Administration (FDA). The AI-based diagnostic system named IDx-DR, which has been developed by privately-held AI diagnostics company IDx, is the first device to be authorized for marketing that provides a screening decision without the need for a clinician to also interpret the image or results. This means that the device can also be used by health care providers who may not normally be involved in eye care.
Read More
24 Apr 2018
AI-Based Platform Designed to Classify Strokes Quickly
An artificial intelligence (AI)-based stroke diagnosis platform designed to assist doctors in quickly classifying the cause of a stroke has completed clinical trials and is expected to provide key information to determine treatment for stroke, leading to faster and more-precise decision-making for patients.
Read More
24 Apr 2018
Breast Density Assessment Software Receives FDA Clearance
The US Food and Drug Administration (FDA) has given 510(k) clearance to a machine learning breast density assessment software that empowers radiologists with standardized, personalized and automated density reports to optimize women’s breast health and follow-up care decisions. The software is now cleared for clinical use in the US, Europe, Canada and Australia, and is the first of several follow-on products to be launched by Densitas Inc., a developer of breast imaging analytics.
Read More
19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
18 Apr 2018
Breast Imaging Market Worth USD 7 Billion by 2024
The global breast imaging market size was estimated at USD 2.9 billion in 2016 and is expected to reach USD 7.3 billion by 2024, driven by the increasing prevalence of breast cancer and other breast-related diseases such as infections, lesions and fibrocysts, as well as supportive government initiatives to increase awareness.
Read More
17 Apr 2018
Veritas Capital Acquires IT Unit of GE Healthcare
Veritas Capital, a private equity investment firm, has entered into a definitive agreement with General Electric, to acquire the Enterprise Financial Management (Revenue-Cycle, Centricity Business), Ambulatory Care Management (Centricity Practice Solution) and Workforce Management (formerly API Healthcare) assets comprising GE Healthcare’s Value-Based Care Division for USD 1.05 billion in cash.
Read More
16 Apr 2018
Interactive VR Assists in Treatment Planning
Interactive virtual reality (VR) shows a patient's unique internal anatomy to interventional radiologists in order to help physicians effectively prepare and tailor their approach to complex treatments, such as splenic artery aneurysm repair. In a new study, researchers compared the VR technology to the use of images from a commonly used visualization software system that displays images on a standard two-dimensional platform and found the accuracy to be similar with both methods, though confidence improved substantially with VR.
Read More
05 Apr 2018
New AI Technique Dramatically Improves Quality of Medical Imaging
Researchers have developed a new technique based on artificial intelligence (AI) and machine learning that enables radiologists to acquire higher quality images without having to collect additional data at the cost of increased radiation dose for computed tomography (CT) and positron emission tomography (PET) or uncomfortably long scan times for magnetic resonance imaging (MRI).
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions